Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Listed as NCT00003287, this PHASE3 trial focuses on Colorectal Cancer and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amadora, Portugal , Antwerp, Belgium , Bayonne, France , Bergen, Norway , Brussels, Belgium , Brussels (Bruxelles), Belgium , Charleroi, Belgium , Chieti, Italy , Clermont-Ferrand, France , Croix, France and 26 more locations